Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumors × TH 302 × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 1 Sarcoma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Esophageal Neoplasms 1 Castration Resistant Prostate Cancer 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

Sunitinib 4 Cyclophosphamide 4 Capecitabine 4 Bevacizumab 4 pazopanib 3 Topotecan 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 temsirolimus 2 liposomal doxorubicin 2 fludarabine 2 Sorafenib 2 Panobinostat 2 NVP-BKM120 2 Lapatinib 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Bortezomib 2 vadimezan 1 spartalizumab 1 somatostatin receptor 2 1 selinexor 1 selicrelumab 1 perifosine 1 pegylated granulocyte colony-stimulating factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01485042 2017-09-01

PATH

Duke University

Phase 1 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡